<DOC>
	<DOCNO>NCT00005598</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Amifostine may improve blood count patient myelodysplastic syndrome . Combining azacitidine amifostine may kill cancer cell . PURPOSE : Phase II trial study effectiveness azacitidine plus amifostine treating patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Azacitidine Plus Amifostine Treating Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate azacitidine plus amifostine patient myelodysplastic syndrome . II . Evaluate toxicity treatment regimen patient . III . Assess rate progression acute myeloid leukemia overall survival patient treat regimen . IV . Evaluate relationship response status cytogenetics , FAB class , ras mutation , presence nonclonal hematopoiesis treatment regimen patient . V. Assess effect treatment regimen number bone marrow hematopoietic progenitor cell patient . VI . Evaluate neutrophil adhesion chemotaxis patient treatment regimen . OUTLINE : Patients receive amifostine IV 1-3 minute day 8 , 10 , 12 , 15 , 17 , 19 , 22 , 24 , 26 plus azacitidine subcutaneously day 1-7 . Treatment repeat every 28 day 4 course . Patients achieve complete remission receive additional 3 course , patient achieve hematologic improvement partial remission continue treatment disease progression unacceptable toxicity . Patients follow death . PROJECTED ACCRUAL : A total 17-32 patient accrue study within approximately 2 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytologically confirm myelodysplastic syndrome ( MDS ) Intermediate 1 , 2 , high risk disease OR Low risk disease one following : Symptomatic anemia require transfusion least 3 month prior study Symptomatic thrombocytopenia require platelet transfusion Platelet count le 50,000/mm3 Absolute neutrophil count le 1,000/mm3 infection Stable disease 1 month progression acute myeloid leukemia Declined eligible allogeneic bone marrow transplant ( alloBMT ) No prior treatment MDS chemotherapy alloBMT No prior leukemia 30 % myeloblast bone marrow PATIENT CHARACTERISTICS : Age : Over 18 Performance status : 02 Life expectancy : Greater 4 month Hematopoietic : See Disease Characteristics Hepatic : Bilirubin le 1.5 time normal ( unless due hemolysis ineffective erythropoiesis ) AST ALT less 2 time normal Renal : Creatinine le 1.5 time normal Cardiovascular : No uncontrolled severe congestive heart failure Pulmonary : Serum CO2 great 18 mmHg Other : No uncorrected folate vitamin B12 deficiency HIV negative No medical psychiatric illness would preclude study At least 3 year since prior nonleukemic malignancy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 1 month since prior interferon , interleukin3 , interleukin11 At least 1 month since prior epoetin alfa , filgrastim ( GCSF ) , sargramostim ( GMCSF ) No concurrent hematologic growth factor Chemotherapy : See Disease Characteristics Prior chemotherapy nonleukemic malignancy allow No prior azacitidine Endocrine therapy : At least 1 month since prior corticosteroid danazol No concurrent steroids Radiotherapy : Prior radiotherapy nonleukemic malignancy allow Surgery : Not specify Other : No prior antithymocyte globulin cyclosporine No prior amifostine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>refractory anemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>